# A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects

> **NCT05049083** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** New Process SHR2554 tablet、Former Process SHR2554 tablet
- **DRUG:** Former Process SHR2554 tablet、New Process SHR2554 tablet

## Key facts

- **NCT ID:** NCT05049083
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-17
- **Primary completion:** 2022-01-06
- **Final completion:** 2022-04-29
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05049083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05049083, "A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05049083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*